AngioDynamics CEO receives 62,928-unit stock grant

The two restricted-stock-unit awards have separate vesting dates, while performance rights depend on revenue, adjusted EBITDA and peer-relative total shareholder return.

Available on EDGAR 11/04/2026 - 06:57 PM EST Accepted by SEC EDGAR 11/04/2026 - 06:56 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

AngioDynamics (ANGO) President and CEO Eric Honroth received 62,928 restricted stock units and 38,265 replacement restricted stock units on November 2, 2026; the latter replaced equity compensation forfeited at his prior employer. Both awards vest in installments subject to continued employment. He also received performance rights with a target of 62,928 common shares, tied to a three-year performance period.

Insider Trade Summary

Grant/Award: 164,121 shares

Grant/Award 3 txns

Insider Honroth Eric

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Performance Right F3	62,928	$0.00	$0.00
Grant/Award	Common Stock F1	62,928	$0.00	$0.00
Grant/Award	Common Stock F2	38,265	$0.00	$0.00

Holdings After Transaction: Performance Right — 62,928 contracts (Direct); Common Stock — 101,193 shares (Direct)

Footnotes (3)

1. F1. The acquisition of 62,928 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company") represents 62,928 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments consistent with awards granted to other executive officers of the Company and beginning on July 15, 2027, such that 25% of the restricted stock units will vest on each of July 15, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continued employment through each applicable vesting date.
2. F2. The acquisition of 38,265 shares of Common Stock represents 38,265 restricted stock units granted to replace equity compensation the Reporting Person forfeited at his prior employer, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in two equal annual installments, such that 50% of the restricted stock units will vest on each of November 2, 2027 and November 2, 2028, subject to the Reporting Person's continued employment through each vesting date.
3. F3. Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned, if at all, based on a combination of the Company's revenue, adjusted EBITDA, and total shareholder return ("TSR") relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement to the extent relative TSR over the three-year performance period exceeds the 75th percentile or is below the 25th percentile (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

Key Figures

Restricted stock units: 62,928 units Replacement restricted stock units: 38,265 units Performance-right target: 62,928 common shares +2 more

5 metrics

Restricted stock units 62,928 units Award reported November 2, 2026

Replacement restricted stock units 38,265 units Award reported November 2, 2026

Performance-right target 62,928 common shares Target number reported November 2, 2026

Performance-right earned range 0% to 200% of target Three-year performance period

Potential aggregate performance-right payout Up to 240% of target Performance-based award

Key Terms

restricted stock units, performance right, adjusted EBITDA, total shareholder return

4 terms

restricted stock units financial

"represents 62,928 restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

performance right financial

"Each performance right represents a contingent right"

adjusted EBITDA financial

"revenue, adjusted EBITDA, and total shareholder return"

Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.

total shareholder return financial

"total shareholder return ("TSR") relative to a peer group"

Total shareholder return is the overall gain an investor gets from owning a stock, combining changes in the share price plus any cash payouts like dividends, and assuming those payouts are reinvested in more shares. Investors use it like a single score that shows the true return on their investment—similar to checking both the growth of a savings account and the interest earned—to compare how well different companies or investments perform over time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many restricted stock units did Eric Honroth receive from ANGO?

He received a 62,928-unit award and a separate 38,265-unit award. Both were reported on November 2, 2026, and the 38,265 units replaced equity compensation he forfeited at his prior employer.

When do Eric Honroth's ANGO restricted stock units vest?

The 62,928 units vest in four equal annual installments on July 15, 2027, 2028, 2029 and 2030. The 38,265 replacement units vest in two equal annual installments on November 2, 2027 and 2028. Both schedules require continued employment through each applicable vesting date.

How are Eric Honroth's ANGO performance rights determined?

The earned amount may range from 0% to 200% of target, based on AngioDynamics' revenue, adjusted EBITDA and total shareholder return relative to a peer group over three years. Relative TSR above the 75th percentile or below the 25th percentile may adjust calculated achievement by 20%, with a potential aggregate payout of up to 240% of target. Unvested shares are forfeited.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Honroth Eric

(Last) (First) (Middle)

14 PLAZA DRIVE

(Street)

LATHAM NEW YORK 12110

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ANGIODYNAMICS INC [ ANGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/02/2026		A		62,928(1)	A	$0	62,928	D
Common Stock	11/02/2026		A		38,265(2)	A	$0	101,193	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Right	(3)	11/02/2026		A		62,928		(3)	(3)	Common Stock	62,928	$0	62,928	D

Explanation of Responses:

1. The acquisition of 62,928 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company") represents 62,928 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments consistent with awards granted to other executive officers of the Company and beginning on July 15, 2027, such that 25% of the restricted stock units will vest on each of July 15, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continued employment through each applicable vesting date.

2. The acquisition of 38,265 shares of Common Stock represents 38,265 restricted stock units granted to replace equity compensation the Reporting Person forfeited at his prior employer, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in two equal annual installments, such that 50% of the restricted stock units will vest on each of November 2, 2027 and November 2, 2028, subject to the Reporting Person's continued employment through each vesting date.

3. Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned, if at all, based on a combination of the Company's revenue, adjusted EBITDA, and total shareholder return ("TSR") relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement to the extent relative TSR over the three-year performance period exceeds the 75th percentile or is below the 25th percentile (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

	/s/ Lawrence T. Weiss, as Attorney in Fact	11/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)